凉血活血中药对咪喹莫特诱导小鼠银屑病样皮损模型IL-23/IL-17炎症轴的作用

目的观察凉血活血中药对咪喹莫特诱导小鼠银屑病样皮损模型白细胞介素-23/白细胞介素-17(IL-23/IL-17)炎症轴的干预作用。方法 BALB/c雄性小鼠随机分为正常组,模型组,凉血活血中药高、中、低剂量组,采用银屑病皮损严重程度指数(PASI)评分观察银屑病样小鼠模型皮损动态变化;光镜观察皮损组织病理变化;采用酶联免疫法(ELISA)、荧光定量PCR、蛋白免疫印迹分析技术检测小鼠血清及皮损中细胞因子含量、mRNA、蛋白的表达水平。结果凉血活血中药高、中、低剂量组小鼠皮肤红斑的出现、色泽及浸润范围、鳞屑面积、鳞屑厚度、皮肤增厚均小于同期的模型组改变(P0.01或P0.05)。HE染色显示:凉血活血中药组小鼠皮肤表皮层较平整,角化不全的细胞明显减少,表皮层厚度明显低于模型组(P0.01)。皮损蛋白及mRNA检测显示,凉血活血中药组小鼠皮肤中IL-17、IL-23蛋白及IL-23mRNA、IL-22mRNA、孤独核受体γt(RORγt)mRNA表达水平均低于模型组(P0.01或P0.05)。结论凉血活血中药可抑制咪喹莫特诱导的银屑病样炎症爆发的强度及银屑病样皮损的形成,可能与降低IL-23/IL-17轴相关细胞因子蛋白和mRNA表达水平,并抑制Th17细胞分化转录因子RORγt mRNA的表达有关。     

甲氨蝶呤治疗寻常型银屑病疗效观察及对Th17细胞相关转导因子影响

目的：研究观察甲氨蝶呤治疗寻常型银屑病的疗效以及对Th17细胞相关转导因子的影响。方法：选择确诊为寻常型银屑病的患者80例,随机分为观察组和对照组,各组均为40例,观察组予以甲氨蝶呤5～15 mg/周,对照组予以阿维A0.5～0.65mg/（kg·d）,均规律服药12周,治疗前和治疗后对进行PASI评分评价疗效,采用亲和素－生物素过氧化物酶复合物酶联免疫吸附试验（ABC－ELISA）分别测量观察组治疗前和治疗后血清中的IL-17, IL-23,IL-16含量。结果：观察组治疗有效率明显高于对照组,前者有效率为92.5%,后者有效率为60%;观察组主要不良反应为胃肠道反应,对照组主要不良反应为头痛、口干、口唇炎、瘙痒等,停药后均能恢复正常。治疗后血清中IL-17,IL-23,IL-16含量低于治疗前。结论：甲氨蝶呤在寻常型银屑病的治疗效果好,毒副作用少,值得推广,治疗后能够降低Th17细胞相关转导因子的含量。     

克银合剂治疗血热型白疕疗效及对肿瘤坏死因子-α的影响

目的 研究克银合剂治疗血热型白疕(寻常型银屑病)疗效及对肿瘤坏死因子-α(TNF-α)的影响.方法 选取30例寻常型银屑病血热型患者作为研究对象,进行克银合剂治疗,另选取同期接受健康体检的健康人30例作为对照组,研究克银合剂对TNF-α的影响.结果 治疗前TNF-α水平显著高于健康对照组,进行克银合剂治疗后患者症状、体征评分均显著低于治疗前,各项指标水平已经接近对照组.结论 克银合剂能改善寻常型银屑病血热型患者的临床症状,对TNF-α异常也有一定的改善作用.     

Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation

ABSTRACT

Introduction: Psoriasis is a chronic inflammatory systemic disease that affects 2% of the population and is associated with an important physical and physiological burden. About 0.5–2% of psoriatic cases onset during the pediatric age range, and often it’s not diagnosed until adulthood. Adalimumab is an antitumor necrosis factor monoclonal antibody approved for use in children in 2008 and now it was used in several diseases in rheumatology, gastroenterology, and in dermatology.

Areas covered: The purpose of this article was to summarize what has been described in the literature so far, about safety in the use of adalimumab in pediatric psoriasis. The presented data was extrapolated from a literature review from PubMed searches (using words ‘pediatric psoriasis,’ ‘adalimumab children,’ ‘adalimumab safety,’ ‘pediatric psoriasis treatment,’ ‘adalimumab clinical trial’), treatment guidelines, and reports from European and United States regulatory agencies.

Expert opinion: Actually there are some biologic agents for the treatment of pediatric psoriasis, but the lack of safety data from controlled trials is evident. The safety data on the use of adalimumab in pediatric psoriasis was taken from long-term studies in the adult population. These studies confirm the data on the safety of the drug as it is also supported by several works on real-life.     

Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections

Treatment of psoriasis and psoriatic arthritis in patients with concomitant chronic, severe viral infections, particularly HIV or HBV, represents a challenge, due to contraindication to conventional immunomodulating systemic drugs and biologics, including anti-TNF alpha, anti-IL12/23, and anti-IL17 agents. Recently, apremilast, a selective inhibitor of phosphodiesterase E4 has been suggested to be a safe and effective therapeutic option in HIV-infected population with psoriatic arthritis. We report the case of a patient with psoriatic arthritis and concomitant HIV and HBV infection successfully treated with apremilast.     

甘肃省河西地区银屑病流行病学调查研究*

目的通过对甘肃省河西地区3个市居民进行流行病学调查,分析本地区银屑病患病情况。方法采用整群抽样法在河西地区3个市中选取17 302名居民,采用问卷调查、临床检查等方法评估居民银屑病患病情况,观察银屑病的流行病学特征,分析其主要危险因素。结果 17 302名调查对象中,确诊银屑病97例,总患病率为0.56%。不同城市、年龄、性别、婚姻状况、文化程度和职业的居民银屑病患病率比较差异无统计学意义(P0.05),而家族史、吸烟史、感染史、精神状态、饮酒及食用羊肉与银屑病发病具有密切相关性。结论河西地区银屑病发病率与全国平均水平基本一致,该病在人口学分布方面比较平均,多种因素均会促进疾病的发生。     

MicroRNAs在银屑病发病机制中的研究进展

近年来在MicroRNAs（miRNAs）与银屑病的相关研究中发现，其在银屑病的发病机制中扮演了重要角色，包括调控T细胞、细胞因子、固有免疫及调节角质形成细胞增殖分化、皮肤屏障等方面。miRNAs在血清和组织中均可以稳定存在，未来可能成为银屑病诊断、评价疾病严重程度、监测治疗后反应及预后的新的标志物。本文对miRNAs在银屑病发病机制中的研究进展进行了综述。     

司库奇尤单抗治疗七例银屑病疗效评价

目的：评价司库奇尤单抗治疗银屑病的疗效和安全性。方法：选取中重度斑块状银屑病患者及泛发性脓疱型银屑病患者，给予司库奇尤单抗,300 mg/次，0～4周每周一次，后每4周一次，并分别于治疗前、1周后、4周后、8周后记录斑块状银屑病患者的银屑病皮损面积和严重度指数(PASI)、泛发性银屑病患者银屑病症状量表(PSS)评分。结果：共治疗6例斑块状银屑病和1例脓疱型银屑病患者，所选的患者均接受至少8周的司库奇尤单抗治疗，起效时间为（1.6±0.73)天；治疗4周时，6例斑块状银屑病患者中全部达到PASI 75，3例达到PASI 90；脓疱型患者PSS评分为2。治疗8周时6例斑块状银屑病患者均达到PASI 100；脓疱型患者PSS评分为0。所有患者治疗期间均未出现严重的药物不良反应。结论：司库奇尤单抗治疗中重度银屑病起效迅速，疗效显著，不良反应少。     

Neutrophil/platelet to lymphocyte ratio in monitoring of response to TNF‐α inhibitors in psoriatic patients

Neutrophil or platelet to lymphocyte ratio (NLR and PLR) has been proposed to be used as prognostic purposes in a variety of diseases. The aim of this study was to evaluate the usefulness of these ratios in monitoring of response to TNF‐α‐inhibitors in psoriatic patients. Eighty psoriatic patients were included and treated with TNF‐α‐inhibitors for 12 months based on drug protocol. Hematologic indices, including NLR and PLR values were assessed before and after treatment. Data on psoriasis area and severity index (PASI), smoking behavior, alcohol intake habit, nail abnormality, body mass index (BMI), joint involvement, and disease duration were also recorded. PASI scores were improved significantly after one‐year treatment (P = .000). Furthermore, this type of treatment significantly reduced the NLR and PLR (P = .000). These changes were in accordance with PASI scores. Patients with BMI greater than 24.9 had higher, but non‐significant NLR and PLR than normal or lean individuals. Cigarette smokers and alcohol consumers had lower NLR and PLR values than other individuals (P < .05). There was no significant association between NLR and PLR and joint or nail involvement. Although NLR and PLR will not be helpful in primary diagnosis of inflammatory diseases, they could be accounted as monitoring tools in management of psoriasis or globally indicators of inflammation.